Although GW Pharma (NASDAQ: GWPH) might not be a pot stock in the traditional sense, sales of the company's cannabidiol (CBD)-based drug, Epidiolex, have been growing at an impressive rate. With the company's second CBD-based drug, Nabiximols, set to begin phase 3 trials soon, there's a lot of excitement surrounding GW Pharma right now. Is now the right time to buy GW Pharma?